Literature DB >> 23278131

Efficacy of mass antimicrobial treatment of foals with subclinical pulmonary abscesses associated with Rhodococcus equi.

M Venner1, K Astheimer, M Lämmer, S Giguère.   

Abstract

BACKGROUND: Mass antimicrobial treatment of foals with small subclinical ultrasonographic pulmonary lesions is empirical practice on many farms with endemic disease caused by Rhodococcus equi. HYPOTHESIS: Mass antimicrobial treatment of foals with subclinical ultrasonographic pulmonary lesions is unnecessary. ANIMALS: One hundred and eight foals on a farm endemic for infections caused by R. equi.
METHODS: Controlled, randomized, and double-blinded prospective study. Foals with ultrasonographic evidence of pulmonary abscesses 5.0-10 cm in diameter (n = 108) were randomly allocated in 5 treatment groups: (1) tulathromycin IM; (2) doxycycline monotherapy PO; (3) doxycycline with rifampin PO; (4) azithromycin with rifampin PO, and (5) saline IM as a placebo. Physical examination and thoracic ultrasonography were performed by individuals unaware of treatment group assignment. Foals with evidence of disease progression were removed from the study and treated with azithromycin-rifampin.
RESULTS: Overall, 22/25 (88%) foals in the placebo group recovered without the need for treatment. The proportion of foals that had evidence of disease progression did not differ significantly between the treatment groups (P > .05). Although the median duration of treatment was significantly (P < .05) shorter in foals treated with azithromycin-rifampin (46 days) compared with foals treated with the placebo (73 days), the time frame of ultrasonographic lesion resolution did not differ significantly between the treatment groups. CONCLUSIONS AND CLINICAL IMPORTANCE: The majority of foals with subclinical pulmonary abscesses <10 cm in diameter recover without antimicrobial treatment and treatment of affected foals does not provide a clear benefit over administration of a placebo.
Copyright © 2012 by the American College of Veterinary Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23278131     DOI: 10.1111/jvim.12030

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  14 in total

1.  Comparison of Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus equi.

Authors:  Londa J Berghaus; Steeve Giguère; Kristen Guldbech; Eleanor Warner; Ukachi Ugorji; Roy D Berghaus
Journal:  J Clin Microbiol       Date:  2014-11-05       Impact factor: 5.948

Review 2.  Epidemiology and Molecular Basis of Multidrug Resistance in Rhodococcus equi.

Authors:  Sonsiray Álvarez-Narváez; Laura Huber; Steeve Giguère; Kelsey A Hart; Roy D Berghaus; Susan Sanchez; Noah D Cohen
Journal:  Microbiol Mol Biol Rev       Date:  2021-04-14       Impact factor: 11.056

3.  Efficacy of gamithromycin for the treatment of foals with mild to moderate bronchopneumonia.

Authors:  F Hildebrand; M Venner; S Giguère
Journal:  J Vet Intern Med       Date:  2015-01       Impact factor: 3.333

4.  Gallium maltolate as an alternative to macrolides for treatment of presumed Rhodococcus equi pneumonia in foals.

Authors:  Noah D Cohen; Nathan M Slovis; Steeve Giguère; Samantha Baker; M Keith Chaffin; Lawrence R Bernstein
Journal:  J Vet Intern Med       Date:  2015-04-13       Impact factor: 3.333

5.  Influence of Plasmid Type on the Replication of Rhodococcus equi in Host Macrophages.

Authors:  Jennifer M Willingham-Lane; Londa J Berghaus; Steeve Giguère; Mary K Hondalus
Journal:  mSphere       Date:  2016-10-12       Impact factor: 4.389

6.  Efficacy of Tulathromycin for the Treatment of Foals with Mild to Moderate Bronchopneumonia.

Authors:  D Rutenberg; M Venner; S Giguère
Journal:  J Vet Intern Med       Date:  2017-04-19       Impact factor: 3.333

7.  Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi.

Authors:  Erdal Erol; Mariela Scortti; Jordan Fortner; Mukesh Patel; José A Vázquez-Boland
Journal:  J Clin Microbiol       Date:  2021-07-28       Impact factor: 5.948

8.  Composition and Diversity of the Fecal Microbiome and Inferred Fecal Metagenome Does Not Predict Subsequent Pneumonia Caused by Rhodococcus equi in Foals.

Authors:  Canaan M Whitfield-Cargile; Noah D Cohen; Jan Suchodolski; M Keith Chaffin; Cole M McQueen; Carolyn E Arnold; Scot E Dowd; Glenn P Blodgett
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

9.  Enrofloxacin and macrolides alone or in combination with rifampicin as antimicrobial treatment in a bovine model of acute Chlamydia psittaci infection.

Authors:  Annette Prohl; Markus Lohr; Carola Ostermann; Elisabeth Liebler-Tenorio; Angela Berndt; Wieland Schroedl; Michael Rothe; Evelyn Schubert; Konrad Sachse; Petra Reinhold
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

10.  Clinical Assessment of a Point-of-Care Serum Amyloid A Assay in Foals with Bronchopneumonia.

Authors:  S Giguère; L J Berghaus; C D Miller
Journal:  J Vet Intern Med       Date:  2016-06-14       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.